Weekly Retail Sales Tracker for Hem. Malignancies - Week Ended June 5

Research evidence excerpt

Weekly Retail Sales Tracker for Hem. Malignancies - Week Ended June 5

Quick Note

June 14, 2026 Biotechnology

Weekly Retail Sales Tracker for Hem. Malignancies - Week

Analysts Ended June 5

David Nierengarten, Ph.D.

(415) 274-6862

David.Nierengarten@wedbush.com

Robert Driscoll, Ph.D. In this weekly report we provide updated IQVIA prescription data for select, FDA-

(415) 274-6863 approved branded hematology-oncology drugs distributed through retail drug

Robert.Driscoll@wedbush.com channels in the U.S. market only, through the Week Ended June 5. This report is

Martin Fan, Ph.D. meant to serve as a guide for evaluating trends in branded retail drug use in the(213) 688-3404

Martin.Fan@wedbush.com US and should not be relied upon for definitive accuracy as a number of dynamics

Dennis Pak may influence the reported numbers.

(415) 263-6647 Key components of the report:Dennis.Pak@wedbush.com

Geoffrey Von Der Ahe ● Script Data by Select Drug Class or Indication: In this section we provide a

(628) 223-0517 summary of IQVIA script data for select drugs organized by pertinent drug class

geoffrey.vonderahe@wedbush.com or indication. Drug classes or indications we’re currently tracking include:

■ Drugs for AML

■ MKIs for CML

■ BTK Inhibitors

■ JAK Inhibitors

● Drug Snapshots: This section provides a one page snapshot of select

FDA approved drugs for hematologic malignancies. Information includes

basic identifying information (manufacturer, drug target/mechanism, route of

administration and dosing schedule, approval history, drug label, and current

monthly price), as well as weekly retail channel sales estimates (TRx MBS

Dollars), New (NRx), Repeat (RRx) and Total (TRx) weekly script count, weekly

prescriber number (Writer Rx), and New (NRx), Repeat (RRx) and Total (TRx)